Targets for immunotherapy in early-stage breast cancer

18 julio 2014

A new molecular analysis tool has been used to detect the level of an important target for immunotherapy in early-stage breast cancers, researchers report. The diagnostic test, using RNAScope, measures the amount of PD-L1 mRNA in cancer tissues and is devoid of many of the technical issues that plague antibody-based detection methods that have yielded conflicting results in the past. PD-L1 is the target of several novel immune stimulatory therapies in clinical trials.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/uoGdu93aMvg/140718131510.htm

Volver